pharma · Inflammatory Bowel Disease (IBD) · Melanoma · IRON
Disc Medicine
Disc Medicine is a pharma organization headquartered in Watertown, USA. It trades on NYSE under ticker IRON. Primary therapeutic focus areas include Inflammatory Bowel Disease (IBD), Melanoma, Parkinson's disease, Falcip
Company details
- Status
- Public
- HQ
- 321 Arsenal St., Suite 101, Watertown, Massachusetts 02472-5710, US
- Employees
- 165
- Programs
- 308
- Drugs
- 443
- Patents
- 706
Mektovi film-coated tablets for metastatic colorectal cancer wi…
Phase 2 · small molecule · metastatic colorectal cancer with a proven RAS mutation after failure of standard systemic treatment regimens including at least 5- FU/capecitabine-oxaliplatin and irinotecan based standard treatment (unless contra-indications for either oxaliplatin or irinotecan)
Mektovi film-coated tablets for metastatic colorectal cancer wi… for metastatic colorectal cancer with a proven RAS mutation after failure of standard systemic treatment regimens including at least 5- FU/capecitabine-oxaliplatin and irinotecan based standard treatment (unless contra-indications for either oxaliplatin or irinotecan) is a Phase 2 program (small_molecule) at Disc Medicine with 1 ClinicalTrials.gov record(s).
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Disc Medicine
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- metastatic colorectal cancer with a proven RAS mutation after failure of standard systemic treatment regimens including at least 5- FU/capecitabine-oxaliplatin and irinotecan based standard treatment (unless contra-indications for either oxaliplatin or irinotecan)
- Status
- active
- Trials
- 1